Clinical trials: Differentiated Thyroid Carcinoma
Hepatocellular Carcinoma, Renal Cell Carcinoma
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
This is a research study of an experimental drug called ACC-1898. ACC-1898 is an oral tyrosine kinase inhibitor (TKI) that blocks several proteins kinases which may help cancer cells grow and spread.
- Conditions
- Hepatocellular Carcinoma, Renal Cell Carcinoma, Thyroid Carcinoma, Medullary, Thyroid Carcinoma Primary Differentiated
- Trial name
- NCT07252661
- Testing
- ACC-1898
- Volunteers
- 40 people
- Sponsor
- AccSalus Biosciences, Inc.
Urothelial Carcinoma, Renal Cell Carcinoma
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types…
- Conditions
- Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT03170960
- Testing
- cabozantinib, atezolizumab
- Where
- 124 sites in United States, Australia and 7 more
- Volunteers
- 914 people
- Sponsor
- Exelixis
Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body…
- Conditions
- Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Kaposi Sarcoma
- Trial name
- NCT04514484
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Thyroid Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to compare the progression free survival, overall response rate (ORR) and safety of participants treated with lenvatinib 24 mg by continuous once…
- Trial name
- SELECT (NCT01321554)
- Testing
- Lenvatinib
- Where
- 155 sites in United States, Argentina and 21 more
- Volunteers
- 392 people
- Sponsor
- Eisai Inc.
Differentiated Thyroid Cancer
An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
This Expanded Access Program (EAP) consists of a Prerandomization Phase and a Randomization Phase. Only subjects with radioiodine-refractory DTC who fulfill the eligibility criteria will be treated.
- Trial name
- NCT02211222
- Testing
- Lenvatinib
- Where
- 13 sites in United States
- Sponsor
- Eisai Inc.
Thyroid, Metastasis
Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers
The purpose of this study is to determine Safety and Efficacy of Radioactive Iodine (RAI) Treatment of Metastatic and Advanced Differentiated Thyroid Cancers by Pretreatment With Apatinib for the Neoadjuvant Regimen
- Conditions
- Thyroid, Metastasis, Apatinib
- Trial name
- APT-01 (NCT04180007)
- Testing
- Apatinib
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Differentiated Thyroid Cancer
A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.
Patients diagnosed with thyroid cancer are commonly treated with surgery to remove their thyroid gland followed by radioiodine ablation to destroy any remaining parts of the thyroid gland that may have been missed during surgery.
- Trial name
- NCT00295763
- Testing
- Thyrogen (thyrotropin alfa for injection)
- Where
- 9 sites in United States, Canada and 3 more
- Volunteers
- 61 people
- Sponsor
- Genzyme, a Sanofi Company
Thyroid Cancer
Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid Cancer
To explore the efficacy and safety of selective coverage radiotherapy in poorly differentiated and anaplastic thyroid cancer
- Trial name
- NCT07777536
- Testing
- Selective coverage radiotherapy, comprehensive coverage radiotherapy
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Fudan University
Thyroid Cancer, Lymph Node Metastasis
The Usefulness of Staining Lymph Nodes During Operations for Cancer Thyroid in Detecting the Nodes That Have Cancer
Detection of lymph nodes starting to be involved by cancer spreading from the thyroid gland during operation is useful. It saves the patient from having a second operation to remove these nodes later on when they become obvious.
- Trial name
- NCT00794053
- Testing
- detecting lymph node metastasis by staining
- Where
- Egypt
- Volunteers
- 45 people
- Sponsor
- University of Alexandria
Thyroid Cancer
rhTSH-Thyroid Ablation With 1850 MBq of 131I
Most patients with differentiated thyroid carcinoma (DTC) are treated with therapeutic doses of radioiodine (131I) after initial surgery (total or near total thyroidectomy), aimed to destroy microscopic residual normal or tumoral…
- Trial name
- NCT00454077
- Testing
- radioiodine therapy after rhTSH
- Where
- Italy
- Volunteers
- 72 people
- Sponsor
- University of Siena
DTC - Differentiated Thyroid Cancer, Thyroid Stimulating; Hormone, C
Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment
Subjects: patients with postoperative local recurrent or metastatic differentiated thyroid cancer . Experimental group: Recombinant human thyroid stimulating hormone injection: 0.9mg/1.0mL/piece; intramuscular injection; once a…
- Conditions
- DTC - Differentiated Thyroid Cancer, Thyroid Stimulating; Hormone, C, Radiotherapy; Complications
- Trial name
- NCT06405217
- Testing
- Recombinant Human Thyroid Stimulating Hormone
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Thyroid Cancer
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
The researchers are doing this study to find out if the combination of avutometinib and defactinib is an effective treatment for RAF dimer-driven radioiodine-refractory differentiated thyroid cancer or anaplastic thyroid cancer.
- Trial name
- NCT06007924
- Testing
- Avutometinib, Defactinib
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Thyroid Cancer
UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone
This is a Phase 2 Study of Everolimus and Lenvatinib in patients with metastatic differentiated thyroid cancer who have progressed on lenvatinib alone. Patient will have imaging, lab test and physical exams
- Trial name
- NCT03139747
- Testing
- Lenvatinib, Everolimus
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Thomas Jefferson University
Differentiated Thyroid Cancer
Tracheal Replacement Using A Cryopreserved Aortic Allograft For R0 Resection In Locally Advanced Thyroid Cancer (TRITON 02 Tracheal Replacement In ThyrOid caNcer)
Airway transplantation remains a great surgical and biological challenge. This is still an unsolved problem for patients in therapeutic impasse because of major tracheobronchial lesions requiring surgical resection and airway…
- Trial name
- TRITON 02 (NCT07823686)
- Testing
- Tracheal replacement using a cryopreserved aortic allograft for R0 resection in locally advanced thyroid cancer, Conventional treatment
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Neuroendocrine Tumors
Capecitabine and Temozolomide for Neuroendocrine Cancers
This phase II study is designed to assess whether treatment with capecitabine/temozolomide (CAP/TEM) is safe and effective in treating subjects with progressive, differentiated, metastatic neuroendocrine tumors (NET).
- Trial name
- NCT00869050
- Testing
- Capecitabine, Temozolomide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Columbia University
Thyroid Cancer, Intermediate Risk
Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up
This trial is comparing two strategies in intermediate-risk differentiated thyroid cancer patients: Systematic radioiodine administration versus decision of radioiodine treatment guided by a post-operative work-up based on serum…
- Trial name
- INTERMEDIATE (NCT04290663)
- Testing
- Systematic RAI-treatment, Decision of RAI-treatment guided by a post-operative assessment
- Where
- 29 sites in France
- Volunteers
- 368 people
- Sponsor
- Centre Francois Baclesse
Thyroid Neoplasms
Study of Clinical Outcomes of Thyroid Cancer
The Italian Thyroid Cancer Observatory (ITCO) repository was established to collect data on thyroid cancer management in a prospective and consecutive series of newly-diagnosed patients, enrolled in centers uniformly distributed…
- Trial name
- ITCO (NCT04031339)
- Testing
- Standard treatment
- Where
- 35 sites in Italy
- Volunteers
- 15,000 people
- Sponsor
- University of Roma La Sapienza
Papillary Thyroid Cancer, Pediatric Cancer
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females.
- Conditions
- Papillary Thyroid Cancer, Pediatric Cancer, Differentiated Thyroid Cancer
- Trial name
- NCT05024929
- Testing
- Whole body scan
- Where
- 9 sites in United States, Australia
- Volunteers
- 32 people
- Sponsor
- Children's Hospital of Philadelphia
Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma
Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer
This phase II trial studies how well lenvatinib works when given together with standard of care iodine I-131 in treating patients with radioactive iodine-sensitive differentiated thyroid cancer.
- Conditions
- Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma
- Trial name
- NCT03506048
- Testing
- Lenvatinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Emory University
Radioactive Iodine-refractory Differentiated Thyroid Cancer
Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer
This is a single arm, open-label, non-randomized and single-center phase II clinical study, to evaluate the safety, tolerance, and efficacy of Camrelizumab in combination with Apatinib in patients with Radioactive…
- Trial name
- NCT04560127
- Testing
- Camrelizumab combination with Apatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital